RxDoctor Payments Data

Peggy Wanner-Barjenbruch, MD

Internal Medicine · Mexico, MONPI 1326023185

Payments from drug & device makers

$776in general payments, 2019–2025

Across 36 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$116
  • AbbVie$101
  • Otsuka America Pharmaceutical, Inc.$94
  • AstraZeneca$89
  • Amgen$65
  • Dexcom, Inc.$45
  • plus $265 from 13 others
$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$150

What the payments were for

  • Food & beverage$776100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$776 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$207,260
Medicare patients
428
Services billed
2,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$176,176
OzempicSemaglutide133$130,615
EliquisApixaban237$119,194
JardianceEmpagliflozin95$85,664
MounjaroTirzepatide71$84,852
FarxigaDapagliflozin Propanediol119$75,910
JanuviaSitagliptin Phosphate53$23,969
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog31$23,030
RexultiBrexpiprazole30$21,466
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$20,710
VraylarCariprazine Hcl12$20,116
TrulicityDulaglutide18$17,276
LinzessLinaclotide25$17,172
XareltoRivaroxaban32$15,039
Breo ElliptaFluticasone/Vilanterol28$13,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$116$130,615133 claims
PfizerEliquis, Abrysvo$14$128,452267 claims
Lilly USA, LLCMounjaro, Trulicity$35$102,12889 claims
AstraZenecaFarxiga, Symbicort$89$88,159156 claims
GSKBreo Ellipta, Trelegy Ellipta, Arexvy, Shingrix, Incruse Ellipta$19$43,237114 claims
AbbVieVraylar, Linzess, Synthroid$101$41,285127 claims
Otsuka America Pharmaceutical, Inc.Rexulti$94$21,46630 claims
Johnson & JohnsonXarelto$32$15,03932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Mexico

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →